skip to main content

CPPD Haemochromatosis Screen — SCE Rheumatology MCQ

Instant feedback + full explanation. One question, done properly.

HardCrystal ArthropathyCPPD Haemochromatosis ScreenSCE Rheumatology

A patient receiving sarilumab 200 mg every 2 weeks for relapsing PMR has an end-of-interval neutrophil count of 0.8 × 10⁹/L on repeat testing. There is no infection. What does the PMR-specific SmPC instruction require?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: C — Discontinue sarilumab; PMR does not use the rheumatoid-arthritis dose-reduction table

Explanation lettering: C = shown as A · D = shown as B · A = shown as C · E = shown as D · B = shown as E

A is correct. PMR has indication-specific stopping rules: sarilumab is discontinued if the end-of-interval ANC is below 1 × 10⁹/L. The withhold-and-resume-at-150 mg table applies to rheumatoid arthritis and should not be imported into PMR, where dose modifications have not been studied. This distinction is easily missed when the same biological drug is used across indications.

Reference: Kevzara 200 mg pre-filled pen SmPC: https://www.medicines.org.uk/emc/product/15436/smpc